Knight Therapeutics (KHTRF)

Knight Therapeutics (KHTRF) Stock Price & Analysis


KHTRF Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.15 - $4.24
Previous Close$3.85
Average Volume (3M)9.44K
Market Cap
Enterprise Value$360.56M
Total Cash (Recent Filing)C$130.50M
Total Debt (Recent Filing)C$79.20M
Price to Earnings (P/E)-83.9
Mar 21, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding104,360,736
10 Day Avg. Volume2,920
30 Day Avg. Volume9,436
Standard Deviation0.07
Financial Highlights & Ratios
Price to Book (P/B)1.37
Price to Sales (P/S)4.50
Price to Cash Flow (P/CF)-92.50
P/FCF Ratio101.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside20.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3



Ownership Overview

85.55% Insiders
1.89% Mutual Funds
0.67% Other Institutional Investors
11.88% Public Companies and
Individual Investors


What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was $3.15 and its highest was $4.24 in the past 12 months.
    What is Knight Therapeutics’s market cap?
    Currently, no data Available
    When is Knight Therapeutics’s upcoming earnings report date?
    Knight Therapeutics’s upcoming earnings report date is Mar 21, 2024 which is in 109 days.
      How were Knight Therapeutics’s earnings last quarter?
      Knight Therapeutics released its earnings results on Nov 09, 2023. The company reported $0.066 earnings per share for the quarter, beating the consensus estimate of -$0.023 by $0.089.
        Is Knight Therapeutics overvalued?
        According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Knight Therapeutics pay dividends?
          Knight Therapeutics does not currently pay dividends.
          What is Knight Therapeutics’s EPS estimate?
          Knight Therapeutics’s EPS estimate is $0.
            How many shares outstanding does Knight Therapeutics have?
            Knight Therapeutics has 104,360,730 shares outstanding.
              What happened to Knight Therapeutics’s price movement after its last earnings report?
              Knight Therapeutics reported an EPS of $0.066 in its last earnings report, beating expectations of -$0.023. Following the earnings report the stock price went up 2.89%.
                Which hedge fund is a major shareholder of Knight Therapeutics?
                Currently, no hedge funds are holding shares in KHTRF


                Company Description

                Knight Therapeutics

                Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Daré Bioscience
                Aldeyra Therapeutics
                Aurinia Pharmaceuticals

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis